Many diseases are caused due to aging and targeting that process can be handy in treating those diseases and improving quality of daily life. EPFL researcher’s have reported that a pomegranate derived compound shows promising signs towards achieving this goal. In human clinical trials, the fruit-derived compound showed that it can slow mitochondrial aging in elderly patients without any side effects.
The compound, urolithin A (UA) showed positive impact in extending lifespans of worms and mice. It improves the functions of mitochondria and hence slows the aging process. Biomolecules in pomegranate breaks down into UA in the human gut as it is not found in any food naturally.
UA compound was synthesized by EPFL team and was tested for its safety and effectiveness on 60 elderly subjects with various oral doses ranging from 250 to 2000 mg over a 28-day period. A controlled group received a placebo, while others were divided into 4 groups, each getting a different daily oral dose of UA: 250mg, 500mg, 1000mg.
No side effects were observed, and this ignited a spark that UA compound can slow down the aging process.
Mr Vinod Arora, Principal Advisor, IGMPI
Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like